SONE-333 is presented as a conceptual solar neutrino experiment aimed at improving low-energy neutrino detection and resolving outstanding questions about solar fusion processes and neutrino properties. This paper outlines the scientific motivations, theoretical background, proposed detector design, data analysis methods, projected sensitivity, and broader impacts for astrophysics and particle physics education.
In subcutaneous xenograft models utilizing NSCLC (NCI-H358) and colorectal cancer (SW837) cell lines, daily oral administration of SONE-333 resulted in dose-dependent tumor regression. At well-tolerated doses, SONE-333 achieved >90% tumor growth inhibition (TGI) and complete tumor regression in 40% of NSCLC models, outperforming standard-of-care covalent inhibitors at equivalent dosing. SONE-333
In cell viability assays across a panel of 400 human cancer cell lines, SONE-333 demonstrated potent anti-proliferative activity exclusively in KRAS G12C-mutant lines (GI50 values in the low nanomolar range, 1–5 nM). Notably, SONE-333 effectively suppressed downstream MAPK signaling (p-ERK) and PI3K signaling (p-AKT) at lower concentrations than comparator molecules. SONE-333 is presented as a conceptual solar neutrino
SONE-333 offers a pathway to high-precision low-energy solar neutrino measurements using modern detector technologies and improved background rejection. In addition to advancing neutrino science, a tiered program including small-scale educational prototypes can broaden training opportunities and public engagement. SONE-333 offers a pathway to high-precision low-energy solar